BR112012008325A2 - N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitótico - Google Patents
N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitóticoInfo
- Publication number
- BR112012008325A2 BR112012008325A2 BR112012008325A BR112012008325A BR112012008325A2 BR 112012008325 A2 BR112012008325 A2 BR 112012008325A2 BR 112012008325 A BR112012008325 A BR 112012008325A BR 112012008325 A BR112012008325 A BR 112012008325A BR 112012008325 A2 BR112012008325 A2 BR 112012008325A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pyridinyl
- pyrimidinyl
- thienyl
- oxy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 5
- JHNQUFYUNLAKGE-UHFFFAOYSA-N 5-[2-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine Chemical compound NC1=NC=CC(=N1)C=1C(=NC=CC1)OC1=C(C=CC=C1)C1=C2C(=NN=C(C2=CC=C1)N)C=1SC=C(C1)C JHNQUFYUNLAKGE-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003080 antimitotic agent Substances 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940123877 Aurora kinase inhibitor Drugs 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 230000002927 anti-mitotic effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003719 aurora kinase inhibitor Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- IVUGFMLRJOCGAS-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine Chemical compound CC1=CSC(C=2C3=CC=CC=C3C(NC=3C=CC(OC=4C(=CC=CN=4)C=4N=C(N)N=CC=4)=CC=3)=NN=2)=C1 IVUGFMLRJOCGAS-UHFFFAOYSA-N 0.000 abstract 1
- 229940127084 other anti-cancer agent Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
N-4 (- ((3-(2-AMINO-4PIRIMIDINIL)-2-PIRIDINIL) OXI) FENIL)-4-(4-METIL-2-TIENIL)-1-FTALAZINAMINA PARA USO NO TRATAMENTO DE CÂNCER RESISTENTE A AGENTE ANTIMITÓTICO. A presente invenção refere-se a métodos de uso do composto, N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil) oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina ou um sal farmaceuticamente aceitável desse, para o tratamento de cânceres, incluindo tumores sólidos, que se tornaram resistentes ao tratamento com agentes quimioterapêuticos, incluindo agentes anti-mitóticos, tais como taxanos, e / ou outros agentes anticancerígenos, incluindo agentes inibidores de quinases Aurora. A invenção também inclui métodos de tratamento de cânceres refratários para tais tratamentos por administração de uma composição farmacêutica compreendendo o composto a um sujeito com câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24152709P | 2009-09-11 | 2009-09-11 | |
| PCT/US2010/048247 WO2011031842A1 (en) | 2009-09-11 | 2010-09-09 | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012008325A2 true BR112012008325A2 (pt) | 2017-08-29 |
Family
ID=43216900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012008325A BR112012008325A2 (pt) | 2009-09-11 | 2010-09-09 | N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitótico |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20120028917A1 (pt) |
| EP (2) | EP2818170B1 (pt) |
| JP (1) | JP5851403B2 (pt) |
| KR (1) | KR20120082896A (pt) |
| CN (1) | CN102869361A (pt) |
| AU (1) | AU2010292225C1 (pt) |
| BR (1) | BR112012008325A2 (pt) |
| CA (1) | CA2773838C (pt) |
| CL (1) | CL2012000640A1 (pt) |
| CR (1) | CR20120171A (pt) |
| DK (1) | DK2475368T3 (pt) |
| EA (1) | EA020526B1 (pt) |
| ES (1) | ES2528485T3 (pt) |
| HK (2) | HK1173655A1 (pt) |
| HR (1) | HRP20150104T1 (pt) |
| HU (1) | HUE024568T2 (pt) |
| IL (1) | IL218569A0 (pt) |
| MA (1) | MA33658B1 (pt) |
| ME (1) | ME02048B (pt) |
| MX (1) | MX2012003041A (pt) |
| NZ (1) | NZ598758A (pt) |
| PE (1) | PE20120895A1 (pt) |
| PL (1) | PL2475368T3 (pt) |
| PT (1) | PT2475368E (pt) |
| RS (1) | RS53807B1 (pt) |
| SG (1) | SG179102A1 (pt) |
| SI (1) | SI2475368T1 (pt) |
| SM (1) | SMT201500028B (pt) |
| TN (1) | TN2012000110A1 (pt) |
| TW (1) | TW201121956A (pt) |
| UA (1) | UA107675C2 (pt) |
| WO (1) | WO2011031842A1 (pt) |
| ZA (1) | ZA201202472B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8921367B2 (en) | 2012-05-31 | 2014-12-30 | Amgen Inc. | Use of AMG 900 for the treatment of cancer |
| CN103664737A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| US9963701B2 (en) | 2013-09-30 | 2018-05-08 | Korea Institute Of Radiological & Medical Sciences | Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor |
| DK3068393T5 (da) | 2013-11-11 | 2022-08-22 | Amgen Inc | Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer |
| AU2014357545B2 (en) * | 2013-12-03 | 2018-10-25 | Amgen Inc. | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof |
| CN114634483A (zh) * | 2014-02-21 | 2022-06-17 | 弗洛斯特生物科技有限公司 | 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺 |
| AU2017248807A1 (en) * | 2016-04-15 | 2018-10-25 | Felicitex Therapeutics, Inc. | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005002571A1 (en) * | 2003-07-03 | 2005-01-13 | Cambridge University Technical Services Ltd | Use of aurora kinase inhibitors for reducing the resistance of cancer cells |
| US7560551B2 (en) * | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| JP5280862B2 (ja) | 2006-01-23 | 2013-09-04 | アムジエン・インコーポレーテツド | オーロラキナーゼ調節剤および使用方法 |
| CN101405282B (zh) * | 2006-01-23 | 2015-03-25 | 安姆根有限公司 | 极光激酶调节剂和使用方法 |
| GB0609619D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Combination |
| GB0609621D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
-
2010
- 2010-09-09 WO PCT/US2010/048247 patent/WO2011031842A1/en active Application Filing
- 2010-09-09 JP JP2012528891A patent/JP5851403B2/ja active Active
- 2010-09-09 UA UAA201204585A patent/UA107675C2/ru unknown
- 2010-09-09 SG SG2012017422A patent/SG179102A1/en unknown
- 2010-09-09 KR KR1020127009226A patent/KR20120082896A/ko not_active Application Discontinuation
- 2010-09-09 AU AU2010292225A patent/AU2010292225C1/en active Active
- 2010-09-09 SI SI201030865T patent/SI2475368T1/sl unknown
- 2010-09-09 EA EA201270383A patent/EA020526B1/ru not_active IP Right Cessation
- 2010-09-09 ES ES10755044.4T patent/ES2528485T3/es active Active
- 2010-09-09 EP EP14186203.7A patent/EP2818170B1/en active Active
- 2010-09-09 PE PE2012000323A patent/PE20120895A1/es not_active Application Discontinuation
- 2010-09-09 CN CN2010800512813A patent/CN102869361A/zh active Pending
- 2010-09-09 ME MEP-2015-10A patent/ME02048B/me unknown
- 2010-09-09 HU HUE10755044A patent/HUE024568T2/hu unknown
- 2010-09-09 NZ NZ598758A patent/NZ598758A/en not_active IP Right Cessation
- 2010-09-09 MX MX2012003041A patent/MX2012003041A/es active IP Right Grant
- 2010-09-09 DK DK10755044T patent/DK2475368T3/en active
- 2010-09-09 RS RS20150065A patent/RS53807B1/en unknown
- 2010-09-09 PL PL10755044T patent/PL2475368T3/pl unknown
- 2010-09-09 EP EP10755044.4A patent/EP2475368B1/en active Active
- 2010-09-09 US US12/878,539 patent/US20120028917A1/en not_active Abandoned
- 2010-09-09 CA CA2773838A patent/CA2773838C/en active Active
- 2010-09-09 BR BR112012008325A patent/BR112012008325A2/pt not_active IP Right Cessation
- 2010-09-09 PT PT107550444T patent/PT2475368E/pt unknown
- 2010-09-10 TW TW099130742A patent/TW201121956A/zh unknown
-
2012
- 2012-03-11 IL IL218569A patent/IL218569A0/en unknown
- 2012-03-12 CL CL2012000640A patent/CL2012000640A1/es unknown
- 2012-03-12 TN TNP2012000110A patent/TN2012000110A1/en unknown
- 2012-04-04 MA MA34753A patent/MA33658B1/fr unknown
- 2012-04-04 ZA ZA2012/02472A patent/ZA201202472B/en unknown
- 2012-04-10 CR CR20120171A patent/CR20120171A/es unknown
-
2013
- 2013-01-16 HK HK13100715.9A patent/HK1173655A1/xx not_active IP Right Cessation
- 2013-01-16 HK HK15106028.6A patent/HK1205457A1/xx unknown
-
2015
- 2015-01-28 HR HRP20150104AT patent/HRP20150104T1/hr unknown
- 2015-02-09 SM SM201500028T patent/SMT201500028B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012008325A2 (pt) | N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitótico | |
| BRPI0511139A (pt) | compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente | |
| MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| WO2008089388A3 (en) | Treatment of cancers having resistance to chemotherapeutic agents | |
| ATE456565T1 (de) | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren | |
| MX2010003668A (es) | Derivados de purina sustituidas con primidina. | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| CL2012003680A1 (es) | Compuestos derivados de (1,8) naftiridinas 2,4 diaril sustituidas inhibidores de quinasas; su procedimiento de obtencion; composicion farmaceutica; y su uso para el tratamiento y/o prevencion de cancer, tumor, tumores malignos, entre otros; kit farmaceutico. | |
| DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
| CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
| BR112013032720A2 (pt) | "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados" | |
| CL2008002294A1 (es) | Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer. | |
| MY162514A (en) | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors | |
| UY32251A (es) | Compuestos quimicos | |
| GEP20125469B (en) | Inhibitors of akt activity | |
| IL191832A (en) | Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors | |
| CL2008002243A1 (es) | Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
| EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
| ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |